Test Price
4,800 AED✅ Home Collection Available
HBOC Extended Panel (32 Genes) in UAE | 4800 AED | 2026 DHA Guidelines
تحليل لوحة جينات سرطان الثدي والمبيض الوراثي الممتدة (32 جيناً) في الإمارات | 4800 درهم | معتمدة من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Complimentary post-test telephonic clinical guidance in result interpretation by DHA-licensed experts.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
يوفر هذا الفحص الجيني المتطور تقييماً شاملاً لمخاطر سرطان الثدي والمبيض الوراثي من خلال تحليل 32 جيناً باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS). يضمن الامتثال الكامل لمرسوم القانون الاتحادي رقم 41 لسنة 2024 (المادة 87) وقانون حماية البيانات الشخصية (PDPL) في دولة الإمارات. يتم تقديم خدمة السحب المنزلي بمعايير الجودة العالمية ISO 9001:2015، مع توجيه سريري ما بعد النتيجة لضمان الفهم الدقيق والخطوات الوقائية.
Overview
The HBOC Extended Panel screens 32 genes linked to hereditary breast and ovarian cancer, providing lifetime risk stratification and enabling personalised surveillance or prophylactic strategies. يحدد الفحص الطفرات الجينية الموروثة بدقة متناهية ويدعم القرارات السريرية للأطباء والمرضى.
| Feature | Our HBOC Extended Panel (32 Genes) | Closest Alternative (Single-Gene BRCA1/2) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) – Illumina NovaSeq X equivalent | Sanger Sequencing / targeted PCR |
| Gene Coverage | 32 genes including BRCA1, BRCA2, PALB2, ATM, CHEK2, RAD51C/D, TP53 and more | BRCA1 and BRCA2 only |
| Turnaround Time | 4–5 weeks | 2–3 weeks |
| Diagnostic Sensitivity | 99.9% (validation in high-risk cohorts) | ~95% for coding variants, misses large rearrangements |
| Price in UAE | 4800 AED | ≈ 2000 – 2500 AED |
| Clinical Utility | Comprehensive hereditary cancer risk assessment; guides NCCN/ESMO management | Limited; additional panels often required after negative result |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA License: 61713011) explains:
“This expanded panel is a precision risk-assessment tool—it is not a diagnostic test for active cancer. A negative result does not guarantee absence of future malignancy, and a positive finding must be discussed with an oncologist or genetic counsellor to design a tailored surveillance or prevention plan. I urge patients to never stop prescribed medications without direct consultation, as sudden discontinuation can pose severe health risks.”
⚠️ Critical Safety & Exclusion Criteria
- Medication Warning: Do not discontinue prescribed medication without consulting your doctor.
- Prescription Mandatory: A valid prescription from a DHA-licensed physician is required. Not applicable for surgery clearance, pregnancy, or individuals planning to travel abroad who need immediate medical fitness certificates.
- Minors: Genetic testing for minors is regulated by UAE CDS Law 2026; legal guardian consent and clinical necessity must be documented.
- Emergency Red Flags: If you currently experience breast lumps, abnormal vaginal bleeding, persistent pelvic pain, or unexplained weight loss, seek urgent clinical evaluation before pursuing elective genetic screening.
Patient FAQ & Clinical Guidance
1. What is the HBOC Extended Panel (32 Genes) and who should consider it?
Direct Answer: A comprehensive genetic test evaluating 32 genes linked to hereditary breast and ovarian cancer, recommended for individuals with strong family history of these cancers.
The panel identifies pathogenic variants that significantly increase lifetime cancer risk. Ideal candidates include women and men with multiple relatives diagnosed with breast/ovarian cancer at young ages, bilateral disease, or known familial mutations. Results support personalised screening (MRI, mammogram), risk-reducing surgeries, and cascade testing for relatives.
الجواب المباشر: اختبار جيني شامل يفحص 32 جيناً مرتبطاً بسرطان الثدي والمبيض الوراثي، ويوصى به للأفراد الذين لديهم تاريخ عائلي قوي لهذه السرطانات. يساعد في تحديد الخيارات الوقائية والمراقبة الدورية.
2. How is the performed and what is the turnaround time?
Direct Answer: A simple peripheral blood draw, analysed using Next-Generation Sequencing, yields definitive results within 4 to 5 weeks.
Our VIP mobile phlebotomy team collects a single blood sample in a dedicated EDTA tube at your home or office (8 AM – 11 PM). The sample is transported under continuous cold-chain monitoring to our ISO-certified laboratory. After sequencing, expert bioinformaticians and molecular geneticists interpret the data. Results are reported in accordance with ACMG/AMP guidelines and include variant classification and risk estimation.
الجواب المباشر: يتم سحب عينة دم وريدي بسيطة بإبرة دقيقة، وتحليلها بتقنية التسلسل الجيني من الجيل التالي، وتظهر النتائج خلال ٤ إلى ٥ أسابيع. يتم النقل بسلسلة تبريد معتمدة والتفسير من قبل استشاريي الوراثة الجزيئية.
3. Is my genetic data confidential and how will I receive interpretation?
Direct Answer: All genetic data is encrypted and protected under UAE PDPL; you receive a secure report with complimentary telephonic clinical guidance.
Your sample and results are de-identified and stored in compliance with Federal Decree-Law No. 41 of 2024 and UAE Personal Data Protection Law. The final report is delivered via a password-protected portal. A dedicated genetic counsellor (DHA-licensed) will walk you through the findings, explaining actionable recommendations and, if needed, coordinate with your referring physician to integrate results into your care plan. Direct billing and insurance preapproval are available via WhatsApp +971 54 548 8731.
الجواب المباشر: جميع البيانات الجينية مشفرة ومحمية بموجب قانون حماية البيانات الشخصية الإماراتي، ويتم تسليم التقرير الآمن مع استشارة هاتفية سريرية مجانية لتفسير النتائج.
Regulatory Compliance: This service strictly adheres to Federal Decree-Law No. 41 of 2024 (Art. 87) on genetic testing consent, UAE CDS Law 2026 provisions for minors, and UAE PDPL for personal data privacy. All processing is conducted under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA facility license No. 9834453.
2026 ICD-10-CM Relevant Codes: Z15.01 (Genetic susceptibility to malignant neoplasm of breast), Z15.02 (Genetic susceptibility to malignant neoplasm of ovary), Z84.81 (Genetic susceptibility to other malignant neoplasm). LOINC Code: 81776-9 (Hereditary breast and ovarian cancer syndrome panel – Blood) – loinc.org/81776-9.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians